Interview: This Biotech Could Have the First HIV Cure on the Market

InnaVirVax is one of the most advanced companies in the race to develop an HIV cure. At the SACHS Conference in Basel, we had the opportunity to pick the brain of the CEO, Joël Crouzet, about his company’s progress.

Last week, we reviewed progress in biotech towards an HIV cure, which could hit the market as soon as 2020. InnaVirVax was one of the companies that piqued our interest as a leader in the field, so we were super excited to talk to the CEO, Joël Crouzet, at SACHS Basel.

InnaVirVax is attempting to leverage T cells to develop a functional HIV cure. The company’s lead candidate, VAC-3S, is administered through the company’s vaccine platform, which generates human polyclonal antibodies against 3S, a subunit of the HIV. With the aid of 3S, the virus binds to a certain type of CD4+ T cells and makes them initiate apoptosis.

Joël told us more about the therapy and the company! Check the interview here:

Let's Continue The Conversation

Feel free to send us comments about this article to and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.